Says “on track” to doubling biosimilar revenue by 2027. Says has moved from a pure play generics to a biopharma company. Says “well on track” for mid single digit CAGR. Says underlying growth of Austedo “very strong.” Says has pipeline potential of greater than $10B. Comments taken from Q4 earnings conference call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: